# First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

> **NCT04622774** · PHASE1,PHASE2 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** IMGC936

## Key facts

- **NCT ID:** NCT04622774
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-29
- **Primary completion:** 2023-12-28
- **Final completion:** 2023-12-28
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04622774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04622774, "First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT04622774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*